Julian Minett speaks with Rowan Bell, Senior HR Director at Wellington College China, and Chris Marshall, Founding Partner of School Business Solutions, about the launch of their HR support network, ISCHR, within the K12 arena.

In today’s podcast we are discussing the current challenges regarding A Level results and the future of higher education with Carl Lygo, current CEO and Vice Chancellor of Arden University. Carl is the former CEO of BPP University, an organisation which he scaled dramatically, and is now also Chairman at the University of Applied Sciences Europe and CEO at King Arthur Education Group.

Today we are joined by Allan Fisher, Senior Director, Academics at Emeritus, for the next episode in our Covid series. Allan has over 20 years of experience in distance and online learning and has led higher education provisions across Africa, Asia, GCC and the US. With his extensive and global background in both OPM and higher education, we were interested to understand his views on the implications of Covid moving forward in these markets.

Today we are speaking to Julian Drinkall, CEO of Academies Enterprise Trust, with 58 schools across its portfolio. Julian has a background as CEO in multiple major academic publishers, along with major strategic consultancy experience and running private school groups. As lockdown eases, we were keen to discuss the reopening of schools and to understand Julian’s view on the possible implications of Covid-19 on the wider global education sector.

In this episode of our Covid series, we are speaking to Catherine Cahn to discuss the possible implications of the pandemic on the global education sector. Catherine is the CEO of Twig Education and has successfully led the scaling and expansion of thisaward-winning digital media company that is revolutionising educational delivery on an international basis. As such, we were keen to understand Catherine’s short and long term global view across this critical market.

We are excited to be speaking to Steve Geffon, a highly experienced commercial lead in the eclinical and services market. Steve is the CCO of Science37, an organisation with over 6 years in virtual/decentralised trials. In this podcast, we discuss the possible implications of Covid-19 on this key area in the eclinical space.

We are excited to be speaking to Mark Anderson, Chairman of London Metropolitan University, in the next of our Covid series. Mark is the former Managing Director UK at Pearson and has since worked extensively as a Non-Executive Director and Chair across the edtech space in Europe, as well as supporting higher education, vocational and university settings. With his extensive experience, we were keen to understand Mark’s views on the possible implications of Covid on the wider education space.

Today, we excited to be talking to Curt Uehlein. Curt has a background at both Wall Street English and Apollo global and is now CEO at Berlitz, a 140 year old language education organisation. As an experienced leader in managing all aspects of an international business in 30 countries such as China, Brazil, India, Australia, UK, US, and Germany, we were interested in hearing his views on the possible implications of Covid-19 on the language education globally.

Today I am speaking to Mukhtar Ahmed, who has a career spanning across major CRO’s and significant eclinical businesses for over 25 years. He is currently President of the Science Group at Clarivate, specialising in high growth subscription analytics, data sciences and consulting services to the healthcare, biopharma, medical device, academic research, publishing and corporate R&D sectors. In this podcast, Mukhtar discusses his view on the possible implications of Covid-19 on the wider healthcare space.

In today’s episode of our Covid series, we are joined by Kuno van der Post. Kuno entered the eclinical sector over 15 years ago when transitioning from preclinical. He is now Chief Commercial Officer at Anju Software and is responsible for their commercial activities across the US. In this podcast, Kuno discusses his view on the implications of Covid-19 on the pharmaceutical sector.

1 3 4 5

News & Blog Archive